Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug (Q38847918)

7 September 2017

title

Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug (English)

1 reference

7 September 2017

1 reference

Guillermo Gervasini

1

1 reference

7 September 2017

Nicolas Roberto Robles

series ordinal

2

1 reference

7 September 2017

language of work or name

English

0 references

publication date

7 April 2017

1 reference

Expert Opinion on Investigational Drugs

7 September 2017

published in

1 reference

7 September 2017

volume

26

1 reference

7 September 2017

issue

5

1 reference

7 September 2017

page(s)

651-659

1 reference

Chronic kidney disease as a coronary artery disease risk equivalent

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Neprilysin inhibition in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Increased human brain natriuretic peptide in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Natriuretic peptide metabolism, clearance and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Natriuretic peptides and cardio-renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

C-type natriuretic peptide in vascular physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Interactions between the sympathetic nervous system and the RAAS in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

European drug market entries 2015 with new mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Effect of nesiritide in patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Angiotensin-neprilysin inhibition versus enalapril in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Community-based incidence of acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Nephrosclerosis: a term in quest of a disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1317345

10.1080/13543784.2017.1317345

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference